ICER Says Gene Therapies For Sickle Cell Likely To Improve Lives, But Points To Uncertainties
Executive Summary
The drug pricing watchdog said improvement to patients’ quality and length of life from lovo-cel and exa-cel were likely, but noted ongoing uncertainty around durability and toxicity concerns.